NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71
Published . Updated .
The average one-year price target for NeuroSense Therapeutics (NASDAQCM:NRSN) (DB:H1Z) has been revised to $112.71 / share. This is an increase of 1,507.27% from the prior estimate of $7.01 dated September 11, 2026. These figures represent aggregate analyst targets compiled from
Directly affected
- NRSN NeuroSense Therapeutics
Named in this report.
Indirectly affected
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DOGG FT VEST DJIA DOGS 10 TARGET INCOME ETF
GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- FGSI FT VEST GROWTH STRENGTH & TARGET INCOME ETF
GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDB ISHARES LIFEPATH TARGET DATE 2030 ETF
GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDC ISHARES LIFEPATH TARGET DATE 2035 ETF USD
GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ITDE ISHARES LIFEPATH TARGET DATE 2045 ETF USD
GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
The average one-year price target for NeuroSense Therapeutics (NASDAQCM:NRSN) (DB:H1Z) has been revised to $112.71 / share. This is an increase of 1,507.27% from the prior estimate of $7.01 dated September 11, 2026. These figures represent…
Source: Nasdaq Markets
How far NeuroSense Therapeutics (NRSN) has moved since 2 Oct 2026
Since the first closing price after “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” NeuroSense Therapeutics (NRSN) is -39.51%. The S&P 500 fund (SPY) is -1.08% over the same days, a -38.43% difference versus the market.
Who gains and who loses around NeuroSense Therapeutics (NRSN)
Companies carried with this story
- NRSN NeuroSense Therapeutics
In “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” NeuroSense Therapeutics (NRSN) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names NEUROSENSE THERAPEUTICS LTD in the headline; GA resolved that company to NRSN
- BTCZ T-Rex 2X Inverse Bitcoin Daily Target ETF
In “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DOGG Ft Vest Djia Dogs 10 Target Income Etf
In “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” Ft Vest Djia Dogs 10 Target Income Etf (DOGG) is linked, with no stored direction, medium confidence. Reason on file: GA selected DOGG as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- FGSI Ft Vest Growth Strength & Target Income Etf
For “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” Ft Vest Growth Strength & Target Income Etf (FGSI) is linked, with no stored direction, medium confidence. Reason on file: GA selected FGSI as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDB Ishares Lifepath Target Date 2030 Etf
Ishares Lifepath Target Date 2030 Etf (ITDB) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71.” Reason on file: GA selected ITDB as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDC Ishares Lifepath Target Date 2035 Etf Usd
In “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” Ishares Lifepath Target Date 2035 Etf Usd (ITDC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ITDC as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ITDE Ishares Lifepath Target Date 2045 Etf Usd
Ishares Lifepath Target Date 2045 Etf Usd (ITDE) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71.” Reason on file: GA selected ITDE as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics (NRSN) is the company in “NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71,” the 2 Oct 2026 this story story.
NeuroSense Therapeutics (NRSN) is on the page because The reported development directly names NEUROSENSE THERAPEUTICS LTD in the headline; GA resolved that company to NRSN
T-Rex 2X Inverse Bitcoin Daily Target ETF (BTCZ) is here too. Its reason reads: GA selected BTCZ as a RELATED security because its canonical security name directly matches this event's themes: target. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Price levels for NeuroSense Therapeutics (NRSN)
BTCZ traded between 2.69 and 3.21 across 20 sessions. The latest close on file is 3.06. DOGG traded between 20.68 and 22.21 across 20 sessions. The latest close on file is 21.99. NRSN traded between 2.45 and 4.24 across 10 sessions. The latest close on file is 2.48.
How strong the case is around NeuroSense Therapeutics (NRSN)
46 out of 100
“NeuroSense Therapeutics Consensus Price Target Increased by 1,507.27% to $112.71” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.